Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daylight photodynamic therapy with Metvix cream for multiple actinic keratoses on face and scalp
2008-000991-26Phase 4Completed
- Sponsor
- Department of Dermatology, Bispebjerg Hospital
- Start
- Mar 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of methyl aminolevulinate in actinic keratosis (AK) (2 arms), sponsored by Department of Dermatology, Bispebjerg Hospital. Primary endpoint: Patient response rate at 3 months. Started Mar 2008; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2008-000991-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000991-26.